RxSight 배당금 및 환매

RXST 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (RXST)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.2%
업계 평균 (Medical Equipment)	1.6%
애널리스트 예측 (RXST) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 RXST 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 RXST 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 RXST 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: RXST 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

RxSight 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye

RxSight, Inc. Revises Financial Guidance for the Full Year 2024

RxSight, Inc. to Report Q3, 2024 Results on Nov 07, 2024

We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth

Investing In The Future Of Cataract Surgery: The RxSight Advantage

RxSight, Inc. Increases Earnings Guidance for the Full Year 2024

With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For

RxSight, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching

RxSight: Great Business Model, Stretched Valuations

A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)

Independent Director recently bought US$305k worth of stock

Consensus estimates of losses per share improve by 17%

Now 21% undervalued

RxSight, Inc. has completed a Follow-on Equity Offering in the amount of $99.999984 million.

RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results

RxSight, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

RxSight, Inc. Increases Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

Chief Financial Officer notifies of intention to sell stock

RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation

RxSight, Inc. to Report Q1, 2024 Results on May 06, 2024

Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price

RxSight, Inc. Announces Commercial Launch of its Newest Light Adjustable Lens™?, the LAL+™?, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting

Chief Financial Officer notifies of intention to sell stock

Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?

Consensus estimates of losses per share improve by 13%

CFO & Assistant Secretary notifies of intention to sell stock

Rxsight, Inc. Reiterates Earnings Guidance for the Full Year 2024

Price target increased by 22% to US$57.75

RxSight, Inc., Annual General Meeting, Jun 06, 2024

Independent Director recently bought US$407k worth of stock

RxSight, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CFO & Assistant Secretary notifies of intention to sell stock

Independent Director recently sold US$1.4m worth of stock

Price target increased by 7.3% to US$46.13

Independent Director notifies of intention to sell stock

RxSight Stock: Time To Refocus Following Eye Watering Rally

RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Price target increased by 12% to US$43.00

RxSightinc. Provides Earnings Guidance for Preliminary Unaudited Fourth Quarter 2023 , Preliminary Unaudited Fiscal Year 2023 and for Full-Year 2024

We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth

Price target increased by 8.8% to US$37.00

Price target increased by 8.0% to US$34.75

Independent Director notifies of intention to sell stock

Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%

Rxsight, Inc. Raises Earnings Guidance for the Full Year of 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

RxSight, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Independent Director recently sold US$993k worth of stock

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Independent Director recently sold US$474k worth of stock

Independent Director notifies of intention to sell stock

Independent Director recently sold US$982k worth of stock

Independent Director notifies of intention to sell stock

RxSight, Inc. Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

RxSight, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Price target increased by 9.4% to US$29.00

Price target increased by 8.4% to US$27.83

Price target increased by 10% to US$25.67

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

RxSight, Inc. Revises Earnings Guidance for the Year 2023

Price target increased by 7.4% to US$20.83

Consensus estimates of losses per share improve by 11%

Full year 2022 earnings: EPS exceeds analyst expectations

RxSight, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

RxSight, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

RxSight, Inc. Revises Earnings Guidance for the Year 2022

RxSight, Inc. to Report Q3, 2022 Results on Nov 07, 2022

RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets